SI2680829T1 - Sestavki in metode za ne-kirurško zdravljenje ptoze - Google Patents

Sestavki in metode za ne-kirurško zdravljenje ptoze

Info

Publication number
SI2680829T1
SI2680829T1 SI201231705T SI201231705T SI2680829T1 SI 2680829 T1 SI2680829 T1 SI 2680829T1 SI 201231705 T SI201231705 T SI 201231705T SI 201231705 T SI201231705 T SI 201231705T SI 2680829 T1 SI2680829 T1 SI 2680829T1
Authority
SI
Slovenia
Prior art keywords
ptosis
compositions
methods
surgical treatment
surgical
Prior art date
Application number
SI201231705T
Other languages
English (en)
Inventor
Mark M. D. Silverberg
Original Assignee
Voom, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voom, Llc filed Critical Voom, Llc
Publication of SI2680829T1 publication Critical patent/SI2680829T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D47/00—Closures with filling and discharging, or with discharging, devices
    • B65D47/04—Closures with discharging devices other than pumps
    • B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
    • B65D47/18—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages for discharging drops; Droppers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SI201231705T 2011-03-03 2012-02-24 Sestavki in metode za ne-kirurško zdravljenje ptoze SI2680829T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161448949P 2011-03-03 2011-03-03
US13/218,584 US20120225918A1 (en) 2011-03-03 2011-08-26 Compositions and Methods for Non-Surgical Treatment of Ptosis
US13/270,577 US8357714B2 (en) 2011-03-03 2011-10-11 Compositions and methods for non-surgical treatment of ptosis
EP12709421.7A EP2680829B1 (en) 2011-03-03 2012-02-24 Compositions and methods for non-surgical treatment of ptosis
PCT/US2012/026496 WO2012118704A1 (en) 2011-03-03 2012-02-24 Compositions and methods for non-surgical treatment of ptosis

Publications (1)

Publication Number Publication Date
SI2680829T1 true SI2680829T1 (sl) 2020-02-28

Family

ID=46753678

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231705T SI2680829T1 (sl) 2011-03-03 2012-02-24 Sestavki in metode za ne-kirurško zdravljenje ptoze

Country Status (23)

Country Link
US (8) US20120225918A1 (sl)
EP (2) EP2680829B1 (sl)
JP (1) JP6106100B2 (sl)
KR (1) KR101889392B1 (sl)
CN (1) CN103501771B (sl)
AU (1) AU2012223615B2 (sl)
BR (1) BR112013022094A2 (sl)
CA (1) CA2827285C (sl)
CY (1) CY1122565T1 (sl)
DK (1) DK2680829T3 (sl)
ES (1) ES2750123T3 (sl)
HR (1) HRP20192266T1 (sl)
HU (1) HUE046740T2 (sl)
LT (1) LT2680829T (sl)
MX (1) MX345042B (sl)
PL (1) PL2680829T3 (sl)
PT (1) PT2680829T (sl)
RS (1) RS59636B1 (sl)
RU (1) RU2582392C2 (sl)
SG (1) SG192801A1 (sl)
SI (1) SI2680829T1 (sl)
WO (1) WO2012118704A1 (sl)
ZA (1) ZA201307262B (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
MY168643A (en) 2011-09-20 2018-11-27 Allergan Inc Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
WO2014182610A2 (en) * 2013-05-06 2014-11-13 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
CA2869060A1 (en) * 2014-07-28 2016-01-28 Queen's University At Kingston Dosage forms and methods for diagnosing sympathetic nervous system dysfunction
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CN115006537A (zh) 2016-01-26 2022-09-06 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
CN106726115B (zh) * 2016-12-22 2023-01-20 上海交通大学医学院附属第九人民医院 一种眼睑功能矫正器
CN106938039A (zh) * 2017-03-29 2017-07-11 卢仁华 眼睑下垂的治疗药物
WO2019204401A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
CN108635434A (zh) * 2018-06-24 2018-10-12 吴安相 一种治疗眼睑下垂的侗族中药配方
EP3860592A4 (en) * 2018-11-26 2023-04-19 Cellix Bio Private Limited OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN AND EYE DISEASES
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
JP2023522953A (ja) * 2020-04-23 2023-06-01 オコジェン、インコーポレイテッド ウイルス性結膜炎の処置
US20240156786A1 (en) 2021-03-03 2024-05-16 Voom, Llc Compositions and methods for treatment of blepharitis

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1117588B (de) 1960-09-30 1961-11-23 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates
US3670087A (en) * 1970-10-16 1972-06-13 Miles Lab Method of lowering intraocular pressure
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
DE3227741A1 (de) 1982-07-24 1984-01-26 Hoechst Ag, 6230 Frankfurt 1-phenyl-isochinolinderivate und verfahren zu ihrer herstellung
FR2549015B1 (fr) * 1983-07-13 1986-06-13 Oreal Ensemble compte-gouttes
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US6066675A (en) * 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
AU7081598A (en) * 1997-04-24 1998-11-13 Taisho Pharmaceutical Co., Ltd. Eye drops
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
US5885550A (en) * 1998-07-02 1999-03-23 Vallier; Deandra K. Ophthalmic whitening solution
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US6572849B2 (en) * 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
WO2002026223A2 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
US7780976B2 (en) * 2002-05-30 2010-08-24 Eye Care And Cure, Asia Apparatus and method for delivering controlled quantities of one or more agents to the eye
PL373033A1 (en) * 2002-06-20 2005-08-08 Novartis Consumer Health S.A. Nasal compositions comprising a mucopolysaccharide and propylene glycol
US6806364B2 (en) 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US7022740B2 (en) 2004-04-29 2006-04-04 Leonard Mackles Lubricious ophthalmic solutions
US7618615B2 (en) * 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
JP4942328B2 (ja) * 2004-11-01 2012-05-30 ロート製薬株式会社 ビタミンｂ６類含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP4956981B2 (ja) * 2005-01-05 2012-06-20 大正製薬株式会社 オキシメタゾリン含有水性組成物
JP5275214B2 (ja) 2006-03-17 2013-08-28 ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド 酸化に不安定な成分を含む眼科用安定組成物
US8685439B2 (en) 2006-04-26 2014-04-01 Aciex Therapeutics, Inc. Method for the treatment and prevention of eyelid swelling
US8466203B2 (en) 2006-12-06 2013-06-18 David Choohyun Paik Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
CN101977595A (zh) * 2007-11-08 2011-02-16 阿西克斯医疗公司 用于治疗以及预防眼睑肿胀的组合物
PT2408453T (pt) * 2009-03-17 2022-04-05 Nicox Ophthalmics Inc Formulações oftálmicas de cetirizina e métodos de utilização
WO2010141831A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
CN103140217B (zh) 2010-08-06 2015-08-19 盖尔德马研究及发展公司 用于治疗或预防皮肤病的化合物的组合
EP3181121B1 (en) 2010-12-03 2020-10-28 EPI Health, LLC Pharmaceutical cream compositions comprising oxymetazoline to treat rosacea
EP3578178A1 (en) * 2011-02-15 2019-12-11 Aclaris Therapeutics, Inc. Pharmaceutical composition comprising oxymetazoline
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
KR20150011807A (ko) 2012-05-25 2015-02-02 질리어, 인크. 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
ES2796871T3 (es) 2014-06-11 2020-11-30 Epi Health Llc Formulaciones de oximetazolina estabilizadas y sus usos
WO2016196367A1 (en) 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CN115006537A (zh) 2016-01-26 2022-09-06 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions

Also Published As

Publication number Publication date
HRP20192266T1 (hr) 2020-03-20
HUE046740T2 (hu) 2020-03-30
US20180338953A1 (en) 2018-11-29
CY1122565T1 (el) 2021-01-27
JP6106100B2 (ja) 2017-03-29
PT2680829T (pt) 2019-12-10
EP3653205A2 (en) 2020-05-20
BR112013022094A2 (pt) 2017-06-27
KR20140013013A (ko) 2014-02-04
US8357714B2 (en) 2013-01-22
JP2014506927A (ja) 2014-03-20
LT2680829T (lt) 2019-12-27
WO2012118704A1 (en) 2012-09-07
NZ614719A (en) 2015-05-29
MX345042B (es) 2017-01-16
CN103501771B (zh) 2016-05-11
US20120225920A1 (en) 2012-09-06
CA2827285A1 (en) 2012-09-07
AU2012223615A1 (en) 2013-10-24
US10912765B2 (en) 2021-02-09
US9018240B2 (en) 2015-04-28
US20120225919A1 (en) 2012-09-06
ZA201307262B (en) 2015-02-25
DK2680829T3 (da) 2019-11-18
EP3653205A3 (en) 2020-08-26
SG192801A1 (en) 2013-09-30
MX2013009597A (es) 2014-01-08
PL2680829T3 (pl) 2020-03-31
US20120225918A1 (en) 2012-09-06
US20220218669A1 (en) 2022-07-14
US20160038465A1 (en) 2016-02-11
RU2013142602A (ru) 2015-04-10
RU2582392C2 (ru) 2016-04-27
EP2680829B1 (en) 2019-09-25
AU2012223615B2 (en) 2017-03-02
ES2750123T3 (es) 2020-03-25
CN103501771A (zh) 2014-01-08
US20200009114A1 (en) 2020-01-09
US9867808B2 (en) 2018-01-16
RS59636B1 (sr) 2020-01-31
KR101889392B1 (ko) 2018-08-17
US20200360345A1 (en) 2020-11-19
CA2827285C (en) 2019-05-07
EP2680829A1 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
ZA201307262B (en) Compositions and methods for non-surgical treatment of ptosis
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
EP2603202A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
EP2776567A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF THE CYTOMEGALIA VIRUS
HK1201475A1 (en) Methods and compositions for treating pain
IL250337A0 (en) Preparations for use in the treatment of nephropathy and methods for their preparation
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
EP2684167A4 (en) COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF DISEASES
HK1203049A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
ZA201307649B (en) Methods and compositions for treatment of attention deficit disorder
EP2675458A4 (en) COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
EP2655334A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
ZA201404187B (en) Compositions and methods for treating dental conditions
EP2771341A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2773212A4 (en) METHODS AND COMPOSITIONS USED FOR THE TREATMENT OF AUTISM
EP2766009A4 (en) METHOD AND COMPOSITIONS FOR SKIN TREATMENT
EP2704638A4 (en) TOOLS AND METHOD FOR THE TREATMENT OF BODY DRESSES
IL228205B (en) Compositions and methods for treatment of intracellular damage
IL227924A0 (en) Preparations and methods of use for determining a4he
EP2755668A4 (en) COMPOSITIONS OF HYR1 AND TREATMENT PROCEDURES THEREWITH
EP2670243A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLAUCOMA
EP2696693A4 (en) COMPOSITION AND METHOD FOR THE PROTECTION OF POLYMERS THAT PREVENT AGROPRIATION
EP2667847A4 (en) IMPROVED COMPOSITIONS AND METHODS FOR PERMANENT HAIR TREATMENT
EP2714082A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN